ARKK vs URGN
ARK Innovation ETF (ARKK) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
ARK Innovation ETF (ARKK) common stock listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
ARKK does not have a complete income-statement cache yet.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
ARKK currently screens at market cap $0. URGN currently screens at market cap $1.61B.
Not investment advice. Open the ARKK and URGN stock pages for the full models.
Not investment advice.